TrialCancer research communications2024

A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).

Edward Maldonado et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.